Most stocks drop during this need. Run it up then do secondary well below market. Possible further runup, then fall with secondary, then ultimately fill gap below a buck
thanks for response. but it makes the combined company less financially stable and puts intense pressure on the timeline for profitablilty
looks like it wants to go lower along with most other biotechs. it will take substantive news or insider buying to reverse trend imo. added DCTH today. selling for less than cash, although high burn rate.
i think we fill gap. either we fill gap prior to that date and good news is announced or we dont fill gap prior to that date and then bad news is announced. all imo
he is smart investor - most of his position was bought below $1. right now market is being hit, small caps hit hard. inefficiencies are created - very easy when company is not yet profitable. look for gap to be filled
I have mental stops on way down for portions of position. Its equivalent of synthetic put. My current position is 25% of my peak position, so too not worried about further losses. If it goes really low and story is positive I may load boat. By positive story I mean insider buying, partnering with pharma and/or major clinical advances. If its any consolation the whole sector is down especially smaller caps
technical management is good. BOD, CEO and BD have been inept at finding partner. I suspect it is arrogance - trying to protect territory rather than doing pure license deal. A partner with milestone payments would make them cash flow positive very quickly and would enable serious HDC development rather than the current lip service approach.
nothing substantial beyond putting all eggs in P3 basket. this need not be the case if they recognize the need to license instead of debating sales territory with potential partners. a partnership will enable them to get parallel efforts on track especially the HDCs which may dwarf the impact of current efforts. right now they are paying big salaries to watch the paint dry on autopilot .- Kovner is obviously not an activist shareholder.
it would not surprise me if the new hedgie game is to short companies in need of cash. the danger they face is that volatility can work both ways with potential pop on news.